Company: IMCR
Filing Date: 2025-04-04
Form Type: DEF 14A
Source: 0001140361-25-012123
Chunk: 55

Company: Immunocore Holdings plc
Filing Date: 2025-04-04
Form: DEF 14A
Chunk 55
---
utive directors that were outstanding as of December 31, 2024. None of our non-executive directors held other unvested stock awards as of December 31, 2024. |

| Name                          |     |     Options 
 Outstanding 
         (#) |
| Professor Sir John Bell       |     |      99,171 |
| Roy S. Herbst, M.D., Ph.D.    |     |      48,006 |
| Siddharth Kaul                |     |      33,478 |
| Ranjeev Krishana              |     |      12,925 |
| Robert Perez                  |     |           — |
| Kristine Peterson             |     |      62,684 |
| Professor Sir Peter Ratcliffe |     |      37,386 |
| Travis Coy                    |     |           — |

| (3) | Amounts represent tax equalization gross-up payments for Dr. Herbst and Ms. Peterson with respect to the portion of their income subject to United Kingdom taxation. Amounts reflect the conversion from GBP to USD using the exchange rate of GBP 1.00 to USD 1.2781, which represents an average for fiscal year 2024. |

| (4) | Mr. Krishana was appointed to our board of directors on May 28, 2024. |

| (5) | Mr. Perez has elected to forgo remuneration in respect of his service as a non-executive director. |

| (6) | Mr. Coy resigned as a member of our board of directors effective January 1, 2025, in connection with his appointment as our Chief Financial Officer. While serving on our board of directors, Mr. Coy elected to forgo remuneration in respect of his service as a non-executive director. |

Non-Executive Director Appointment Letters Each of our non-executive directors is engaged on letters of appointment that set out their respective duties and responsibilities. The non-executive directors do not receive benefits upon termination or resignation from their respective positions as directors. Under the non-executive director appointment letters, our non-executive directors are entitled to receive annual fees in accordance with our non-executive director remuneration policy, and in each case inclusive of fees payable for all duties. Non-Executive Director Remuneration Policy In January 2021, in connection with our initial public offering, our board adopted our non-executive director remuneration policy, which was most recently amended in February 2024.